Advertisement
Advertisement
INCY
Incyte Genomics Inc
94.87
USDSponsored
-1.06
-1.11%
Apr 06, 16:00 UTC -4
Closed
After-Market
94.89
+0.02
+0.02%
INCY Earnings Reports
Positive Surprise Ratio
INCY beat 20 of 40 last estimates.
50%
Next Report
Date of Next Report
Apr 27, 2026
Estimate for Q1 26 (Revenue/ EPS)
$1.26B
/$1.46
Implied change from Q4 25 (Revenue/ EPS)
-16.53%
/-18.89%
Implied change from Q1 25 (Revenue/ EPS)
+19.45%
/+26.96%
Incyte Genomics Inc earnings per share and revenue
On Feb 10, 2026, INCY reported earnings of 1.80 USD per share (EPS) for Q4 25, missing the estimate of 1.96 USD, resulting in a -8.46% surprise. Revenue reached 1.51 billion, compared to an expected 1.38 billion, with a 9.27% difference. The market reacted with a -8.24% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 12 analysts forecast an EPS of 1.46 USD, with revenue projected to reach 1.26 billion USD, implying an decrease of -18.89% EPS, and decrease of -16.53% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Pharvaris N.V. Ordinary Shares
Report Date
Apr 02, 2026 For Q4 25
Estimate
-$0.63
Actual
-$0.72
Surprise
-13.69%
Connect Biopharma Holdings Limited Ordinary Shares
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.44
Actual
-$1.91
Surprise
-32.66%
Innate Pharma S.A. ADS
Report Date
Apr 01, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.55
Surprise
-353.80%
Tvardi Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.65
Actual
-$0.78
Surprise
-18.33%
VolitionRX Limited Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.05
Surprise
-22.35%
Cyclerion Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.38
Actual
-$0.21
Surprise
+45.82%
Imunon, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.19
Actual
-$1.99
Surprise
-66.18%
Kairos Pharma, Ltd.
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.07
Surprise
-28.68%
Soligenix, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.57
Actual
-$0.28
Surprise
+50.98%
BioAtla, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$12.24
Actual
-$8.00
Surprise
+34.64%
FAQ
What were Incyte Genomics Inc's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Incyte Genomics Inc reported EPS of $1.80, missing estimates by -8.46%, and revenue of $1.51B, 9.27% above expectations.
How did the market react to Incyte Genomics Inc's Q4 2025 earnings?
The stock price moved down -8.24%, changed from $109.03 before the earnings release to $100.05 the day after.
When is Incyte Genomics Inc expected to report next?
The next earning report is scheduled for Apr 27, 2026.
What are the forecasts for Incyte Genomics Inc's next earnings report?
Based on 12
analysts, Incyte Genomics Inc is expected to report EPS of $1.46 and revenue of $1.26B for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement